Notarkib Biopharmaceutical

Notarkib Biopharmaceutical is a clinical-stage biotechnology company based in Suzhou, China, dedicated to the discovery and development of innovative small molecule therapeutics for oncology and autoimmune diseases. The company focuses on targeting key nodes in the RAS/MAPK signaling pathway and other challenging biological targets often considered undruggable. Its lead clinical candidate, NTQ1062, is a potent and selective SHP2 inhibitor currently being evaluated in Phase 1 trials for patients with advanced solid tumors. Notarkib utilizes a structure-based drug design approach to optimize its pipeline of precision medicines. The leadership team comprises industry veterans with extensive experience in global pharmaceutical R&D. The company aims to address significant unmet medical needs through both monotherapy and combination treatment strategies.